Unlocking Early-Stage Biotech: Dr Amir Zalcenstein on Transformative Science and Venture Capital

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. SYNthesis BioVentures is a registered early-stage venture Capital Limited partnerships fund, focused on early-stage therapeutics investing in projects from discovery through preclinical proof of concept and IND enabling studies. Amir and the team are investing in small molecule therapeutics, biologics and cell and gene therapies for conditions with significant ...